$40.00
+2.20%Price chart
Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$39.82
From 52W high−37.48%
Volume15.16M
Market cap$178.60B
P/E (TTM)10.2x
P/S (TTM)3.6x
Div yield3.74%
Key dataOct 30, 2026
Open
$39.82
From 52W high
−37.48%
Volume
15.16M
Market cap
$178.60B
ValuationView details →
P/E (Fwd)
12.1x
EV/EBITDA
7.1x
P/E (TTM)
10.2x
RSI (14)
53.3
MomentumView details →
1D Return
+2.20%
YTD Return
−21.57%
SummaryUpdated Jun 1, 2026
Novo Nordisk A/S (NYSE:NVO) is a Danish multinational pharmaceutical company founded in 1923 and headquartered in Bagsvaerd, Denmark. The company has evolved from its origins as an insulin manufacturer into a global leader in diabetes care and, more recently, obesity treatment. Novo Nordisk went public in 1981 and has grown to serve over 45 million patients worldwide with diabetes and obesity treatments. The company operates primarily through two business segments: Diabetes and Obesity Care, and Rare Disease, with the former representing the vast majority of its revenue and growth trajectory.
Similar companies
Latest newsMore news →
VEEVA SYSTEMS INC announced that executives from ASTRAZENECA PLC, BRISTOL MYERS SQUIBB CO, Grünenthal GmbH, NOVO NORDISK A S, Roche Holdings, Inc. and UCB SA are among those featured at Veeva Summit, which presents innovations in AI and data for an agent-based commercial model.2d agoEli Lilly said its investigational drug retatrutide was more effective than NOVO NORDISK A S’s Ozempic at lowering blood sugar and reducing weight in a large diabetes study.3d agoEli Lilly and Co reported promising mid-stage data for EloraTZP, an experimental obesity treatment combining eloralintide and tirzepatide, which produced weight loss of up to 23.3% after 48 weeks in overweight or obese patients with type 2 diabetes.30d ago